SXTP · NASDAQ
60 Degrees Pharmaceuticals (SXTP) Stock Price & Fundamentals
60 Degrees Pharmaceuticals (SXTP) closed at $525.40 on Oct 9, 2026, down 0.22% from the previous close of $526.56.
Share price, past year
1Y −16.54%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $525.40 |
| Sep 30, 2026 | $530.41 |
| Aug 31, 2026 | $537.63 |
| Jul 31, 2026 | $545.71 |
| Jun 30, 2026 | $548.88 |
| May 29, 2026 | $518.74 |
| Apr 30, 2026 | $532.41 |
| Mar 31, 2026 | $577.80 |
| Feb 27, 2026 | $572.18 |
| Jan 30, 2026 | $555.13 |
| Dec 31, 2025 | $588.75 |
| Nov 28, 2025 | $616.96 |
| Oct 31, 2025 | $632.43 |
Key statistics
- Market cap
- $1.40B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.65
- Revenue (TTM)
- $1.11M
- Net income (TTM)
- −$8.11M
- Shares outstanding
- 2.7M
- Dividend yield
- —
- 52-week range
- $503.53 – $640.90
60 Degrees Pharmaceuticals's market cap is $1.40B, based on a share price of $525.40 and 2.7M shares outstanding as of Jun 30, 2026.
Financials
60 Degrees Pharmaceuticals reported revenue of $1.01M for fiscal 2025, up 65.49% from fiscal 2024.
60 Degrees Pharmaceuticals reported a net loss of $7.37M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.01M | +65.5% | −$7.37M | −732.5% | −$11.73 | −$6.99M |
| FY2024ended Dec 31, 2024 | $607.57K | +139.6% | −$7.95M | −1,308.0% | −$74.17 | −$5.75M |
| FY2023ended Dec 31, 2023 | $253.57K | +13.6% | −$3.77M | −1,485.1% | −$59.18 | −$4.60M |
| FY2022ended Dec 31, 2022 | $223.21K | — | −$6.18M | −2,769.5% | −$2.61 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $207.90K | −$2.26M | −$0.90 |
| Q1 FY2026ended Mar 31, 2026 | $162.09K | −$2.09M | −$1.28 |
| Q4 FY2025ended Dec 31, 2025 | $303.39K | −$1.44M | $0.19 |
| Q3 FY2025ended Sep 30, 2025 | $437.60K | −$2.32M | −$0.66 |
| Q2 FY2025ended Jun 30, 2025 | $100.93K | −$1.73M | −$5.01 |
| Q1 FY2025ended Mar 31, 2025 | $163.55K | −$1.88M | −$6.25 |
| Q4 FY2024ended Dec 31, 2024 | $241.64K | −$2.05M | −$51.96 |
| Q3 FY2024ended Sep 30, 2024 | $135.29K | −$2.16M | −$2.92 |
Company profile
- Name
- 60 Degrees Pharmaceuticals, Inc.
- Ticker
- SXTP
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1025 Connecticut Avenue Nw, Suite 1000, Washington, DC 20036
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001946563
Recent SEC filings
- Oct 6, 2026
- Sep 14, 2026
- Sep 8, 2026
- Aug 14, 2026
- Aug 6, 2026
- Aug 4, 2026
- Jul 20, 2026
- Jul 9, 2026
Frequently asked questions
What is 60 Degrees Pharmaceuticals's stock price?
60 Degrees Pharmaceuticals (SXTP) closed at $525.40 on Oct 9, 2026, down 0.22% from the previous close of $526.56.
What is 60 Degrees Pharmaceuticals's market cap?
60 Degrees Pharmaceuticals's market cap is $1.40B, based on a share price of $525.40 and 2.7M shares outstanding as of Jun 30, 2026.
How much revenue does 60 Degrees Pharmaceuticals make?
60 Degrees Pharmaceuticals reported revenue of $1.01M for fiscal 2025, up 65.49% from fiscal 2024.
Does 60 Degrees Pharmaceuticals pay a dividend?
60 Degrees Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from 60 Degrees Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures